Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus CERADON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus CERADON.
BREO ELLIPTA vs CERADON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Unknown; possibly enhances cognitive function by modulating cholinergic and dopaminergic pathways.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
500 mg orally every 8 hours; for severe infections, 750 mg every 12 hours or 1 g every 8 hours.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
3-5 hours in healthy adults; prolonged to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 20 hours in severe impairment (CrCl <30 mL/min).
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total: >90% eliminated within 48 hours.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid